Physician profile
Alaa S Eldin
NPI 1548287386
$1,418.81
in general payments reported to CMS, 2019-2025
12 companies · $225 in 2025
The $225 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38.61 · 2020: $214 · 2021: $275 · 2022: $278 · 2023: $301 · 2024: $87.68 · 2025: $225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $613.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $613.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $454.80 | 2019-2024 | Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $434.34 | 2019-2023 | Trulance, Xifaxan |
| Ardelyx, INC. | $235.65 | 2024-2025 | Ibsrela |
| Abbvie INC. | $127.42 | 2021-2025 | |
| Vivus LLC | $31.14 | 2021 | |
| Janssen Biotech, INC. | $29.17 | 2022-2023 | Stelara, Simponi Aria, Simponi |
| Evoke Pharma, INC. | $28.42 | 2020-2021 | |
| Redhill Biopharma INC. | $23.02 | 2020 | |
| Nestle Healthcare Nutrition INC. | $15.00 | 2020 | |
| Ferring Pharmaceuticals INC. | $14.85 | 2023 | Rebyota |
| Concordia Pharmaceuticals INC. | $13.20 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alaa Eldin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.